Prostate Cancer Epidemiology Analysis and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with prostate cancer in their lifetime. However, most are diagnosed after age 65 years, and patients often live long enough that they die of other causes (National Cancer Institute, 2024). Homologous recombination deficiency (HRD) mutations, which affect the DNA repair pathway, increase a man’s risk of contracting prostate cancer (Heeke et al., 2018a, 2018b). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2024).

Scope

This report provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at ages 30 years) and stage at diagnosis (stage I, IIA, IIB, III, IV-M0, and IV-M1). Additionally, this report forecasts five-year diagnosed prevalent cases of prostate cancer segmented by stage (stage I-II, III, and IV-M0 and IV-M1), progressed cases (local and regional to stage IV-M0 and IV-M1), Gleason scores (2–10), metastatic and non-metastatic CRPC cases, and DNA repair mutations in metastatic CRPC (mCRPC) cases. Finally, the epidemiology model corresponding to this report presents prostate cancer diagnosed incident cases by Gleason scores (2–10).

Reasons to Buy

The Prostate Cancer Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global prostate cancer markets.

Quantify patient populations in the global prostate cancer markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the groups that present the best opportunities for prostate cancer therapeutics in each of the markets covered.

Understand magnitude of the prostate cancer population by age, staging, progression and biomarkers.

Table of Contents

List of Contents

List of Tables

List of Figures

About GlobalData

1 Prostate cancer: Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities.

2.3 Global and historical trends

2.4 8MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed incident cases of prostate cancer

2.4.4 Forecast assumptions and methods: diagnosed incident cases of prostate cancer by stage at diagnosis

2.4.5 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer 26

2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer by Gleason scores

2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer by stages

2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer that progress from local and regional to advanced stages

2.4.9 Forecast assumption and methods: five-year diagnosed prevalent cases (metastatic and non-metastatic) that progress from hormone-sensitive disease to CRPC by status

2.4.10 Forecast assumption and methods: five-year diagnosed prevalent cases of prostate cancer by mutations and biomarkers

2.5 Epidemiological forecast for prostate cancer (2023–33)

2.5.1 Diagnosed incident cases of prostate cancer

2.5.2 Age-specific diagnosed incident cases of prostate cancer

2.5.3 Diagnosed incident cases of prostate cancer by stages

2.5.4 Five-year diagnosed prevalent cases of prostate cancer

2.5.5 Five-year diagnosed prevalent cases of prostate cancer by Gleason scores

2.5.6 Five-year diagnosed prevalent cases by stage

2.5.7 Five-year diagnosed prevalent cases of prostate cancer with progression to advanced stages

2.5.8 Five-year diagnosed prevalent cases of prostate cancer that progress from hormone-sensitive disease to CRPC by status

2.5.9 Five-year diagnosed prevalent cases of mCRPC with DNA repair mutations

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 COVID-19 impact

2.6.3 Limitations of the analysis

2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 Primary market research – Prescriber survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Vice President of Disease Intelligence and Epidemiology

3.3.4 Global Head of Pharma Research, Analysis and Competitive Intelligence

Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for prostate cancer

Table 4: High-prescribing physicians surveyed, by country

Figures

Figure 1: 8MM, diagnosed incident cases of prostate cancer, men, N, ages ≥30 years, 2023 and 2033

Figure 2: 8MM, five-year diagnosed prevalent cases of prostate cancer, men, N, ages ≥30 years, 2023 and 2033

Figure 3: 8MM, diagnosed incidence of prostate cancer, men, N, ages ≥30 years, 2013‒33

Figure 4: 8MM, five-year diagnosed prevalence of prostate cancer, men, N, ages ≥30 years, 2017‒33

Figure 5: 8MM, sources used and not used to forecast the diagnosed incident cases of prostate cancer

Figure 6: 8MM, sources used to forecast the diagnosed incident cases of prostate cancer by staging

Figure 7: 8MM, sources used to forecast the five-year diagnosed prevalent cases of prostate cancer

Figure 8: 8MM, sources used to forecast the five-year diagnosed prevalent cases of prostate cancer by Gleason scores

Figure 9: 8MM, sources used to forecast the five-year diagnosed prevalent cases of prostate cancer by staging

Figure 10: 8MM, sources used to forecast the five-year diagnosed prevalent cases of CRPC

Figure 11: 8MM, sources used to forecast the five-year diagnosed prevalent cases prevalent cases of prostate cancer by progression from hormone-sensitive disease to CRPC by status

Figure 12: 8MM, sources used to forecast the five-year diagnosed prevalent cases of mCRPC by DNA repair mutations

Figure 13: 8MM, diagnosed incident cases of prostate cancer, men, N, ages ≥30 years, 2023

Figure 14: 8MM, age-specific diagnosed incident cases of prostate cancer, men, N, ages ≥30 years, 2023

Figure 15: 8MM, diagnosed incident cases of prostate cancer by stage at diagnosis, men, N, ages ≥30 years, 2023

Figure 16: 8MM, five-year diagnosed prevalent cases of prostate cancer, men, N, ages ≥30 years, 2023

Figure 17: 8MM, five-year diagnosed prevalent cases of prostate cancer by Gleason score, men, N, ages ≥30 years, 2023

Figure 18: 8MM, five-year diagnosed prevalent cases by stages, men, N, ages ≥30 years, 2023

Figure 19: 8MM, five-year diagnosed prevalent cases prostate cancer with progression to advanced stage, men, N, ages ≥30 years, 2023

Figure 20: 8MM, five-year diagnosed prevalent cases of prostate cancer that progress from hormone-sensitive disease to CRPC by status, men, N, ages ≥30 years, 2023

Figure 21: 8MM, diagnosed prevalent cases of mCRPC with DNA repair mutations, men, N, ages ≥30 years, 2023

Prostate Cancer Epidemiology Analysis and Forecast to 2033 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Catalyst Monitor: Q2 2026 Outlook
$1,870 | March 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q1 2026
$2,950 | March 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Prostate Cancer Epidemiology Analysis and Forecast to 2033 in real time.

  • Access a live Prostate Cancer Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.